Literature DB >> 18757635

What reasons do those with practical experience use in deciding on priorities for healthcare resources? A qualitative study.

A Hasman1, E McIntosh, T Hope.   

Abstract

BACKGROUND: Priority setting is necessary in current healthcare services. Discussion of fair process has highlighted the value of developing reasons for allocation decisions on the basis of experience gained from real cases. AIM: To identify the reasons that those with experience of real decision-making concerning resource allocation think relevant in deciding on the priority of a new but expensive drug treatment.
METHODS: Semistructured interviews with members of committees with responsibility for making resource allocation decisions at a local level in the British National Health Service, analysed using modified grounded theory.
RESULTS: 22 interviews were carried out. 14 reasons were identified. Four reasons were almost universally considered most important: cost effectiveness; clinical effectiveness; equality and gross cost. No one reason was considered dominant. Some considerations, such as political directives and fear of litigation, were thought by many participants to distort decision-making. There was a substantial lack of agreement over the relevance of some reasons, such as the absence of alternative treatment for the condition.
CONCLUSIONS: There is a clear consensus on the importance and role of a limited number of reasons in allocation decisions among participants. A focus on the process of decision-making, however, does not obviate the need for those involved in the process to engage with problematical ethical issues, nor for the importance of further ethical analysis.

Entities:  

Mesh:

Year:  2008        PMID: 18757635     DOI: 10.1136/jme.2007.023366

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  4 in total

1.  Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden.

Authors:  Nathalie Eckard; Magnus Janzon; Lars-Åke Levin
Journal:  Int J Health Policy Manag       Date:  2014-10-27

Review 2.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

3.  Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Authors:  Peter B Berger; Judson B Williams; Vic Hasselblad; Karen Chiswell; Karen S Pieper; Robert M Califf
Journal:  J Interv Cardiol       Date:  2013-02-05       Impact factor: 2.279

4.  Around the Tables - Contextual Factors in Healthcare Coverage Decisions Across Western Europe.

Authors:  Tineke Kleinhout-Vliek; Antoinette de Bont; Meindert Boysen; Matthias Perleth; Romke van der Veen; Jacqueline Zwaap; Bert Boer
Journal:  Int J Health Policy Manag       Date:  2020-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.